Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies II

IFNγ neutralization by the clinically approved monoclonal antibody emapalumab mitigates severe toxicity related to CAR-T therapy Emapalumab does not impair CAR.CD19 T-cell activation signaling hGM-CSF/hIL3 NOG mice (n=10) were infused with irradiated FF-Luciferase positive Daudi cells at Day-2 and treated with 10x106 CAR.CD19 T-cells/mouse either in the presence of 100mg/Kg/day emapalumab (n=5) or of the vehicle (n=5). Two mice were considered as for negative control, being infused only with DAUDI cells. Mice were sacrified 3 days after CAR T-cell infusion to evaluate the brain damage occurrence in this murine model of acute CAR T-cell toxicity.